Serum Levels of Galectin-9 Are Increased in Cervical Cancer Patients and Are Higher in Advanced Clinical Stages

Purpose: Cervical cancer (CC) is the second most frequent cancer in undeveloped countries. Serum biomarkers could be useful for evaluation of the treatment response and as a complementary means to improve diagnosis. The expression of galectin-9 is altered in cancer tissue, and higher concentrations are found in the serum of cancer patients. The objectives of this study were (a) to determine the serum galectin-9 concentration in patients with intraepithelial lesions and CC, (b) to determine if the concentration was related to the clinicopathological characteristics and (c) to determine if the galectin-9 concentration was related to its expression level in tumour tissue.

Patients And Methods: In all, 222 serum samples from women with different diagnoses, including premalignant lesions and CC, as well as samples from women with normal cytology were included in the study. The serum galectin-9 concentration was determined by ELISA. To evaluate the expression level of galectin-9 in CC tissue, immunohistochemistry was performed in 34 CC biopsy specimens.

Results: The galectin-9 concentration in the serum of CC patients (8.171 ng/mL) was increased compared with serum from women with normal epithelia (4.654 ng/mL) and those with low-grade (4.806 ng/mL) and high-grade (5.354 ng/mL) intraepithelial lesions (p value < 0.0001). The area under the ROC curve considering the CC group and the control group was 0.882. The optimal cut-off value was ≥6.88 ng/mL, the specificity obtained was 100%, and the sensitivity was 68.2%. In the CC group, the analysis of the clinical stage showed an increase of galectin-9 in the advanced stage IV group. Serum galectin-9 was not related to the level of galectin-9 expression in tissue, which suggests that galectin-9 is not secreted by tumour cells.

Conclusion: The serum galectin-9 concentration is related to cancer progression, as the level of this protein is higher in patients with advanced-stage disease.

Citing Articles

The regulating role of galectin-9 in immune cell populations.

Cao Z, Leng P, Xu H, Li X Front Pharmacol. 2024; 15:1462061.

PMID: 39539619 PMC: 11557436. DOI: 10.3389/fphar.2024.1462061.

Expression of Gal-9 on Dendritic Cells and Soluble Forms of TIM-3/Gal-9 in Patients Suffering from Endometriosis.

Suszczyk D, Skiba W, Pawlowska A, Polak G, Tarkowski R, Wertel I Int J Mol Sci. 2023; 24(6).

PMID: 36983021 PMC: 10056739. DOI: 10.3390/ijms24065948.

Response to Article "Serum Levels of Galectin-9 are Increased in Cervical Cancer Patients and are Higher in Advanced Clinical Stages" [Response to Letter].

Reyes-Vallejo T, Conde-Rodriguez I, Serna-Villalobos J, Ramirez-Diaz I, Perez-Villalobos G, Delgado-Lopez G Onco Targets Ther. 2022; 15:1543-1544.

PMID: 36579183 PMC: 9792111. DOI: 10.2147/OTT.S399119.

Response to Article "Serum Levels of Galectin-9 are Increased in Cervical Cancer Patients and are Higher in Advanced Clinical Stages" [Letter].

Panjaitan N, Lienggonegoro L, Nikmah U Onco Targets Ther. 2022; 15:1417-1418.

PMID: 36457761 PMC: 9707536. DOI: 10.2147/OTT.S396547.

References

Zhang L, Tian S, Zhao M, Yang T, Quan S, Yang Q . SUV39H1-DNMT3A-mediated epigenetic regulation of Tim-3 and galectin-9 in the cervical cancer. Cancer Cell Int. 2020; 20:325. PMC: 7370487. DOI: 10.1186/s12935-020-01380-y. View

Seifert A, Reiche C, Heiduk M, Tannert A, Meinecke A, Baier S . Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels. Oncogene. 2020; 39(15):3102-3113. PMC: 7142017. DOI: 10.1038/s41388-020-1186-7. View

Irie A, Yamauchi A, Kontani K, Kihara M, Liu D, Shirato Y . Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res. 2005; 11(8):2962-8. DOI: 10.1158/1078-0432.CCR-04-0861. View

Wdowiak K, Gallego-Colon E, Francuz T, Czajka-Francuz P, Ruiz-Agamez N, Kubeczko M . Increased serum levels of Galectin-9 in patients with chronic lymphocytic leukemia. Oncol Lett. 2019; 17(1):1019-1029. PMC: 6313089. DOI: 10.3892/ol.2018.9656. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Liang M, Lu Y, Zhang Y, Zhang S . [Serum galectin-9 in cervical cancer]. Zhonghua Yi Xue Za Zhi. 2008; 88(39):2783-5. View

Nakajima R, Miyagaki T, Kamijo H, Oka T, Shishido-Takahashi N, Suga H . Possible therapeutic applicability of galectin-9 in cutaneous T-cell lymphoma. J Dermatol Sci. 2019; 96(3):134-142. DOI: 10.1016/j.jdermsci.2019.09.004. View

Zhu C, Anderson A, Schubart A, Xiong H, Imitola J, Khoury S . The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005; 6(12):1245-52. DOI: 10.1038/ni1271. View

Yunes-Diaz E, Ruiz P, Lazcano-Ponce E . Assessment of the Validity and Reproducibility of the Pap Smear in Mexico: Necessity of a Paradigm Shift. Arch Med Res. 2015; 46(4):310-6. DOI: 10.1016/j.arcmed.2015.05.013. View

10.

Heusschen R, Griffioen A, Thijssen V . Galectin-9 in tumor biology: a jack of multiple trades. Biochim Biophys Acta. 2013; 1836(1):177-85. DOI: 10.1016/j.bbcan.2013.04.006. View

11.

Dasari S, Wudayagiri R, Valluru L . Cervical cancer: Biomarkers for diagnosis and treatment. Clin Chim Acta. 2015; 445:7-11. DOI: 10.1016/j.cca.2015.03.005. View

12.

Li X, Chen Y, Liu X, Zhang J, He X, Teng G . Tim3/Gal9 interactions between T cells and monocytes result in an immunosuppressive feedback loop that inhibits Th1 responses in osteosarcoma patients. Int Immunopharmacol. 2017; 44:153-159. DOI: 10.1016/j.intimp.2017.01.006. View

13.

Choi S, Seo K, Kook M, Kim C, Kim Y, Cho S . Prognostic value of tumoral expression of galectin-9 in gastric cancer. Turk J Gastroenterol. 2017; 28(3):166-170. DOI: 10.5152/tjg.2017.16346. View

14.

John S, Mishra R . Galectin-9: From cell biology to complex disease dynamics. J Biosci. 2016; 41(3):507-34. DOI: 10.1007/s12038-016-9616-y. View

15.

Chihara M, Kurita M, Yoshihara Y, Asahina A, Yanaba K . Clinical Significance of Serum Galectin-9 and Soluble CD155 Levels in Patients with Systemic Sclerosis. J Immunol Res. 2019; 2018:9473243. PMC: 6288562. DOI: 10.1155/2018/9473243. View

16.

Daley D, Mani V, Mohan N, Akkad N, Ochi A, Heindel D . Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance. Nat Med. 2017; 23(5):556-567. PMC: 5419876. DOI: 10.1038/nm.4314. View

17.

Goncalves Silva I, Yasinska I, Sakhnevych S, Fiedler W, Wellbrock J, Bardelli M . The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells. EBioMedicine. 2017; 22:44-57. PMC: 5552242. DOI: 10.1016/j.ebiom.2017.07.018. View

18.

Armenta-Castro E, Reyes-Vallejo T, Maximo-Sanchez D, Herrera-Camacho I, Lopez-Lopez G, Reyes-Carmona S . Histone H3K9 and H3K14 acetylation at the promoter of the LGALS9 gene is associated with mRNA levels in cervical cancer cells. FEBS Open Bio. 2020; 10(11):2305-2315. PMC: 7609790. DOI: 10.1002/2211-5463.12973. View

19.

Liu Y, Zhang L, Zhao G, Che L, Zhang H, Fang J . The clinical research of Thinprep Cytology Test (TCT) combined with HPV-DNA detection in screening cervical cancer. Cell Mol Biol (Noisy-le-grand). 2017; 63(2):92-95. DOI: 10.14715/cmb/2017.63.2.14. View

20.

Beyer S, Wehrmann M, Meister S, Kolben T, Trillsch F, Burges A . Galectin-8 and -9 as prognostic factors for cervical cancer. Arch Gynecol Obstet. 2022; 306(4):1211-1220. PMC: 9470666. DOI: 10.1007/s00404-022-06449-9. View